The therapeutic benefits of GLP-1 RAs in HS are attributed to weight loss, which reduces adipose tissue and systemic inflammation
However, tirzepatide was removed from the FDA drug shortage list, triggering restrictions on compounded versions
RossiOxidative stress and human diseases: origin, link, measurement, mechanisms, and biomarkersCrit Rev Clin Lab Sci, 46 (2009), pp
Further, many of the studies did not have information on the dose, duration of usage, duration of holding GLP-1 agonists, and fasting period prior to the procedure
There is a need for large-scale observational studies or head-to-head randomized trials that evaluate whether liraglutide, semaglutide, dulaglutide, and newer dual agonists such as tirzepatide offer different cancer risks or benefits due to their structural differences
Therefore, its important to discuss the pros and cons with a healthcare professional.